Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
Moderna (NASDAQ:MRNA) has officially opened its Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire, UK. The state-of-the-art facility will manufacture mRNA vaccines for the UK population and conduct research in various therapeutic areas.
The facility, which can produce up to 100 million mRNA vaccine doses annually (expandable to 250 million during pandemics), represents a key milestone in Moderna's ten-year strategic partnership with the UK Government. The MITC is the first facility in the UK to manufacture mRNA vaccines onshore and includes Clinical R&D laboratories for analyzing global trial samples.
Under the partnership, Moderna has already conducted over 20 clinical trials across 110 UK sites, becoming the country's largest commercial trial sponsor. The MITC joins Moderna's global manufacturing network, which includes facilities in Australia and Canada.
Moderna (NASDAQ:MRNA) ha inaugurato ufficialmente il Moderna Innovation and Technology Centre (MITC) a Harwell, Oxfordshire, Regno Unito. La struttura all’avanguardia produrrà vaccini mRNA per la popolazione britannica e condurrà ricerche in diverse aree terapeutiche.
La struttura, in grado di produrre fino a 100 milioni di dosi di vaccino mRNA all’anno (espandibile a 250 milioni durante le pandemie), rappresenta una tappa chiave della partnership strategica decennale tra Moderna e il Governo del Regno Unito. Il MITC è la prima struttura nel Regno Unito a produrre vaccini mRNA onshore e comprende laboratori di R&D clinica per l’analisi di campioni di trial globali.
Nell’ambito della partnership, Moderna ha già condotto oltre 20 studi clinici in 110 siti nel Regno Unito, diventando il maggior sponsor di trial commerciali del paese. Il MITC si aggiunge alla rete globale di produzione di Moderna, che comprende impianti in Australia e in Canada.
Moderna (NASDAQ:MRNA) ha inaugurado oficialmente su Centro de Innovación y Tecnología Moderna (MITC) en Harwell, Oxfordshire, Reino Unido. La instalación de última generación fabricará vacunas de ARNm para la población británica y llevará a cabo investigaciones en varias áreas terapéuticas.
La instalación, capaz de producir hasta 100 millones de dosis de vacuna ARNm al año (ampliable a 250 millones durante pandemias), representa un hito clave en la asociación estratégica de diez años de Moderna con el Gobierno del Reino Unido. El MITC es la primera instalación en el Reino Unido que fabrica vacunas de ARNm en suelo británico y alberga laboratorios de I+D clínica para analizar muestras de ensayos globales.
Bajo la asociación, Moderna ya ha llevado a cabo más de 20 ensayos clínicos en 110 sitios del Reino Unido, convirtiéndose en el mayor patrocinador de ensayos comerciales del país. El MITC se suma a la red global de fabricación de Moderna, que incluye instalaciones en Australia y Canadá.
Moderna (NASDAQ:MRNA)는 영국 옥스퍼드셔주 해류엘(Harwell)의 Moderna Innovation and Technology Centre (MITC)를 공식 개관했다. 이 최첨단 시설은 영국 인구를 위한 mRNA 백신을 제조하고 다양한 치료 분야에서 연구를 수행할 것이다.
연간 1억 도스의 mRNA 백신 생산 가능으로, 팬데믹 시에는 2.5억 도스까지 확장 가능하며, 이는 Moderna와 영국 정부 간 10년 간의 전략적 파트너십에서 중요한 이정표가 된다. MITC는 영국 내에서 mRNA 백신을 현지 생산하는 최초의 시설이며 전 세계 임상 샘플을 분석하는 임상 R&D 연구실을 포함한다.
파트너십에 따라 Moderna는 이미 영국 전역 110개 사이트에서 20건이 넘는 임상시험을 수행해 국가에서 가장 큰 상업적 시험 스폰서가 되었다. MITC는 호주와 캐나다의 시설을 포함하는 Moderna의 글로벌 제조 네트워크에 합류한다.
Moderna (NASDAQ:MRNA) a officiellement inauguré son Moderna Innovation and Technology Centre (MITC) à Harwell, dans l’Oxfordshire, au Royaume-Uni. L’installation ultramoderne fabriquera des vaccins à ARN messager pour la population britannique et mènera des recherches dans divers domaines thérapeutiques.
L’installation peut produire jusqu’à 100 millions de doses de vaccin à ARN messager par an (extensible à 250 millions en période de pandémie), marquant une étape clé du partenariat stratégique sur dix ans entre Moderna et le gouvernement britannique. Le MITC est la première installation au Royaume-Uni à fabriquer des vaccins ARNm sur le sol national et comprend des laboratoires de R&D clinique pour analyser les échantillons d’essais mondiaux.
Dans le cadre du partenariat, Moderna a déjà mené plus de 20 essais cliniques sur 110 sites au Royaume‑Uni, devenant le principal sponsor d’essais commerciaux du pays. Le MITC s’ajoute au réseau mondial de fabrication de Moderna, qui comprend des installations en Australie et au Canada.
Moderna (NASDAQ:MRNA) hat offiziell ihr Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire, Großbritannien, eröffnet. Die hochmoderne Anlage wird mRNA‑Impfstoffe für die britische Bevölkerung herstellen und in verschiedenen therapeutischen Bereichen forschen.
Die Einrichtung kann bis zu 100 Millionen Dosen mRNA‑Impfstoffe pro Jahr produzieren (im Pandemiefall auf 250 Millionen erweiterbar) und markiert einen wichtigen Meilenstein in Modernas zehnjähriger strategischer Partnerschaft mit der britischen Regierung. Das MITC ist die erste Einrichtung im Vereinigten Königreich, die mRNA‑Impfstoffe vor Ort herstellt und umfasst klinische F&E‑Laboratorien zur Analyse globaler Studienproben.
Im Rahmen der Partnerschaft hat Moderna bereits über 20 klinische Studien an 110 Standorten im Vereinigten Königreich durchgeführt und ist damit der größte kommerzielle Studien-Sponsor des Landes. Das MITC ergänzt Modernas weltweites Herstellungsnetzwerk, zu dem Einrichtungen in Australien und Kanada gehören.
افتتحت شركة Moderna (بورصة ناسداك: MRNA) رسميًا مركز Moderna للابتكار والتكنولوجيا (MITC) في هارويل، مقاطعة أوكسفوردشاير، المملكة المتحدة. ستقوم المنشأة المتقدمة بتصنيع لقاحات mRNA لسكان المملكة المتحدة وستجري أبحاث في مجالات علاجية متعددة.
يمكن للمرفق أن ينتج حتى 100 مليون جرعة من لقاحات mRNA سنويًا (قابل للزيادة إلى 250 مليون جرعة أثناء الأوبئة)، مما يمثل علامة فارقة في الشراكة الاستراتيجية لمدة عشر سنوات بين Moderna وحكومة المملكة المتحدة. MITC هو أول منشأة في المملكة المتحدة تصنع لقاحات mRNA محليًا ويتضمن مختبرات R&D سريرية لتحليل عينات التجارب العالمية.
في إطار الشراكة، قامت Moderna بالفعل بـ أكثر من 20 تجربة سريرية في 110 مواقع داخل المملكة المتحدة، لتصبح راعي التجارب التجارية الأكبر في البلاد. سينضم MITC إلى شبكة التصنيع العالمية لشركة Moderna، التي تشمل منشآت في أستراليا وكندا.
Moderna (NASDAQ:MRNA) 已正式在英国牛津郡哈威尔开设 Moderna Innovation and Technology Centre (MITC)。这座尖端设施将为英国人口生产 mRNA 疫苗，并在多种治疗领域开展研究。
该设施年产能可达 1亿剂 mRNA 疫苗（在大流行期间可扩展至2.5亿剂），标志着 Moderna 与英国政府为期十年的战略伙伴关系中的一个关键里程碑。MITC 是 英国首个在国内生产 mRNA 疫苗的设施，并设有用于分析全球试验样本的临床研发实验室。
根据伙伴关系，Moderna 已在英国 110 个地点开展了超过 20 项临床试验，成为该国最大的商业试验赞助方。MITC 将加入 Moderna 的全球制造网络，该网络还包括澳大利亚和加拿大的设施。
- First UK facility to manufacture mRNA vaccines onshore, enhancing local supply chain
- Large manufacturing capacity of 100 million doses annually, expandable to 250 million
- Established presence with 20+ clinical trials across 110 UK sites
- Strategic partnership with UK government strengthens market position
- R&D capabilities for global trial analysis enhance research infrastructure
- Significant operational costs associated with maintaining large-scale manufacturing facility
- Potential overcapacity risks if vaccine demand decreases
Insights
Moderna's new UK facility strengthens global manufacturing network, enhances pandemic readiness, and solidifies strategic government partnership.
Moderna's new Innovation and Technology Centre in Oxfordshire represents a significant expansion of the company's global manufacturing footprint. The facility can produce up to
This facility delivers on several strategic objectives for Moderna. First, it operationalizes their ten-year partnership with the UK government, securing a long-term customer relationship with predictable revenue streams through NHS vaccination programs. Second, it positions Moderna as an essential component of the UK's health security infrastructure, creating both political and economic moats around their business in this region.
The rapid two-year timeline from concept to operational facility demonstrates Moderna's execution capabilities and the priority placed on this expansion. By establishing the MITC as part of a global manufacturing hub network that includes Australia and Canada, Moderna is implementing a distributed production strategy that enhances supply chain resilience and positions them to respond more rapidly to future pandemics.
Beyond COVID-19 vaccines, the R&D capabilities at this facility will support Moderna's pipeline development across cancer, rare diseases, and immune disorders. This diversification is crucial as the company works to expand beyond its COVID-19 revenue base and leverage its mRNA platform across multiple therapeutic areas.
The designation of Moderna as "the largest commercial sponsor of trials in the country" with "more than 20 clinical trials across 110 sites" indicates substantial ongoing R&D investment in the UK market, which should accelerate the company's pipeline progress and strengthen relationships with local medical institutions.
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
The facility marks a cornerstone of Moderna's ten-year strategic partnership with the UK Government, designed to strengthen health resilience and drive economic growth
CAMBRIDGE, MA / ACCESS Newswire / September 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK has officially opened. The MITC will now produce British-made mRNA respiratory vaccines for the UK public to support the National Health Service (NHS) seasonal vaccination programs. Beyond respiratory diseases, the MITC will also support research into the potential of mRNA science in areas such as cancer, rare diseases and immune disorders.
"The opening of the Moderna Innovation and Technology Centre marks the first facility in the UK to manufacture an onshore supply of mRNA vaccines," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our strategic partnership with the UK has already delivered more than 20 clinical trials across 110 sites nationwide, making Moderna the largest commercial sponsor of trials in the country. Together, we successfully delivered this vision from concept to operational readiness in under two years. This latest milestone underscores the UK's commitment to improving health security, both against global health emergencies and ongoing seasonal respiratory threats."
The site can produce up to 100 million mRNA vaccine doses per year, with the capacity to increase to 250 million in the event of a pandemic. The Clinical R&D facility at the MITC also includes laboratories that will analyze samples from Moderna's clinical trials globally.
The MITC is part of a global network of advanced manufacturing hubs, alongside facilities in Australia and Canada, that collectively strengthen pandemic readiness by maximizing geographic coverage and minimizing response times.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's strategic partnership with the UK government; details of Moderna's ongoing and planned R&D activities in the UK; the potential applications of Moderna's mRNA platform; and the production capacity and timing for releases of vaccines to be produced at the MITC. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control, and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the manufacturing capacity of Moderna's new UK facility?
Where is Moderna's new UK manufacturing facility located?
How many clinical trials has Moderna conducted in the UK?
What types of vaccines and treatments will be developed at Moderna's UK facility?
How does the UK facility fit into Moderna's global manufacturing network?
